Exchange Announcement • 07 Oct 2026 16:00
Otsuka Completes Rolling Submission Of Supplemental Biologics License Application (Sbla) For Traditional Approval Of Voyxact In U.S.
Exchange Announcement • 02 Oct 2026 07:30
Nda Submission Initiated For Zipalertinib Plus Chemotherapy In First-Line Egfr Exon 20 Insertion Mutation Nsclc For Review Under Fda Rtor Program
Exchange Announcement • 01 Oct 2026 14:30
Notice Regarding The Status Of Share Repurchases
Exchange Announcement • 14 Sep 2026 07:15
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Pfs Benefit In Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Nsclc
Exchange Announcement • 01 Sep 2026 14:30